Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.
作者信息
McKenzie Duncan R, Muñoz-Ruiz Miguel, Monin Leticia, Alaguthurai Thanussuyah, Lechmere Thomas, Abdul-Jawad Sultan, Graham Carl, Pollock Emily, Graham Rosalind, Sychowska Kamila, Seow Jeffrey, Tremain Catherine, Gousis Charalampos, Domingo-Vila Clara, Cooper Jack, Vidler Jennifer, Owczarczyk Kasia, Swampillai Angela, Kristeleit Hartmut, Malim Michael H, Fields Paul, Patten Piers E M, Papa Sophie, North Bernard V, Tree Timothy, Doores Katie J, Hayday Adrian C, Irshad Sheeba
机构信息
The Francis Crick Institute, London, UK.
Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, UK; Breast Cancer Now Research Unit, King's College London, London, UK.
出版信息
Cancer Cell. 2021 Nov 8;39(11):1445-1447. doi: 10.1016/j.ccell.2021.10.003. Epub 2021 Oct 12.
Abstract
摘要
相似文献
1
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.癌症患者对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）BNT162b2 mRNA疫苗延迟第二剂的体液免疫和细胞免疫
Cancer Cell. 2021 Nov 8;39(11):1445-1447. doi: 10.1016/j.ccell.2021.10.003. Epub 2021 Oct 12.
2
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.多发性骨髓瘤完全接种疫苗患者对SARS-CoV-2的细胞反应各异。
Cancer Cell. 2021 Nov 8;39(11):1442-1444. doi: 10.1016/j.ccell.2021.09.015. Epub 2021 Oct 19.
3
Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的重复疫苗接种在异基因干细胞移植受者中引发强大的多功能T细胞反应。
Cancer Cell. 2021 Nov 8;39(11):1448-1449. doi: 10.1016/j.ccell.2021.10.002. Epub 2021 Oct 12.
4
T-cell and Antibody Response After 2 Doses of the BNT162b2 Vaccine in a Belgian Cohort of Kidney Transplant Recipients.比利时肾移植受者队列中两剂BNT162b2疫苗后的T细胞和抗体反应
Transplantation. 2021 Oct 1;105(10):e142-e143. doi: 10.1097/TP.0000000000003892.
5
Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients.透析患者对基于mRNA与腺病毒载体的SARS-CoV-2疫苗的体液反应。
Clin J Am Soc Nephrol. 2021 Nov;16(11):1720-1722. doi: 10.2215/CJN.06450521. Epub 2021 Jul 26.
6
Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.心脏和胸部移植受者对两剂 SARS-CoV-2 信使 RNA 疫苗 BNT162b2 的体液和 T 细胞应答较差。
Clin Res Cardiol. 2021 Aug;110(8):1142-1149. doi: 10.1007/s00392-021-01880-5. Epub 2021 Jul 9.
7
Very Low Immunization Rate in Kidney Transplant Recipients After One Dose of the BNT162b2 Vaccine: Beware not to Lower the Guard!肾移植受者接种一剂BNT162b2疫苗后免疫率极低：谨防放松警惕！
Transplantation. 2021 Oct 1;105(10):e148-e149. doi: 10.1097/TP.0000000000003818.
8
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.血液透析患者中 SARS-CoV-2 mRNA 疫苗的细胞和体液免疫原性。
EBioMedicine. 2021 Aug;70:103524. doi: 10.1016/j.ebiom.2021.103524. Epub 2021 Aug 12.
9
Analysis of humoral and cellular immune activation up to 21 months after heterologous and homologous COVID-19 vaccination.异源和同源新冠病毒疫苗接种后长达21个月的体液免疫和细胞免疫激活分析
Front Immunol. 2025 May 2;16:1579163. doi: 10.3389/fimmu.2025.1579163. eCollection 2025.
10
A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques.单剂 SARS-CoV-2 复制子 RNA 疫苗可诱导感染和未感染 SIV 的食蟹猴产生细胞和体液免疫应答。
Front Immunol. 2021 Dec 21;12:800723. doi: 10.3389/fimmu.2021.800723. eCollection 2021.
引用本文的文献
1
mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.mRNA-1273 疫苗接种可诱导接受免疫治疗和/或化疗的实体瘤患者产生多功能记忆 CD4 和 CD8 T 细胞应答。
Front Immunol. 2024 Aug 27;15:1447555. doi: 10.3389/fimmu.2024.1447555. eCollection 2024.
2
Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis.与健康对照相比，新冠病毒疫苗在血液系统恶性肿瘤患者中的疗效：一项系统评价和荟萃分析
JMA J. 2024 Apr 15;7(2):153-171. doi: 10.31662/jmaj.2023-0171. Epub 2024 Apr 1.
3
Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment.癌症患者对 mRNA 疫苗的反应取决于接种疫苗和最后一次治疗之间的时间间隔。
J Immunother Cancer. 2023 Sep;11(9). doi: 10.1136/jitc-2023-007387.
4
Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2.使用BBIBP-CorV、AZD1222或BNT162b2疫苗完成针对SARS-CoV-2的疫苗接种方案后，血液系统疾病中体液免疫和细胞免疫反应的比较。
Front Med (Lausanne). 2023 Jul 17;10:1176168. doi: 10.3389/fmed.2023.1176168. eCollection 2023.
5
Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia.基于载体的 SARS-CoV-2 疫苗接种与血液系统恶性肿瘤中 T 细胞反应的改善相关。
Blood Adv. 2023 Jul 25;7(14):3403-3415. doi: 10.1182/bloodadvances.2022009054.
6
Effectiveness and Safety of COVID-19 Vaccination in Patients with Malignant Disease.新冠病毒疫苗在恶性疾病患者中的有效性和安全性
Vaccines (Basel). 2023 Feb 20;11(2):486. doi: 10.3390/vaccines11020486.
7
SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants.患有癌症、艾滋病毒或实体器官移植的免疫功能低下个体中的SARS-CoV-2特异性T细胞反应。
Pathogens. 2023 Feb 3;12(2):244. doi: 10.3390/pathogens12020244.
8
Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer.增强癌症患者对 SARS-CoV-2 关切变异株的体液和细胞反应。
Cancer Res Commun. 2022 Nov 17;2(11):1449-1461. doi: 10.1158/2767-9764.CRC-22-0298.
9
Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis.实体瘤癌症患者对 SARS-CoV-2 疫苗体液免疫反应的决定因素：系统评价和荟萃分析。
Vaccine. 2023 Mar 10;41(11):1791-1798. doi: 10.1016/j.vaccine.2023.01.072. Epub 2023 Feb 13.
10
Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8 T cell immunity in CLL and MDS patients.BNT162b2 COVID-19 mRNA 疫苗三剂接种可在 CLL 和 MDS 患者中建立持久的 CD8 T 细胞免疫。
Front Immunol. 2023 Jan 10;13:1035344. doi: 10.3389/fimmu.2022.1035344. eCollection 2022.
Zotero 插件